Bristol-Myers Squibb announces worldwide collaboration with Janssen to develop and commercialize next-generation cardiovascular therapy

Bristol-Myers SquibbBristol-Myers Squibb Company (NYSE: BMY) today announced a worldwide collaboration with Janssen Pharmaceuticals, Inc. (Janssen) on a Factor XIa (FXIa) inhibitor program that includes the development and commercialization of Bristol-Myers Squibb's Factor XIa (FXIa) inhibitor, BMS-986177, an investigational anticoagulant compound being studied for prevention and treatment of major thrombotic conditions. The companies are expected to advance BMS-986177 into Phase 2 clinical trials in the second half of 2018 for the study of secondary stroke prevention.

Thrombotic disorders include cardiovascular conditions such as coronary artery disease, stroke and peripheral artery disease. BMS-986177 is an inhibitor of Factor XIa, and is being explored for its potential to improve upon the standard of care by reducing the risk of vascular events - without increasing the risk of bleeding - in patients with thrombotic disorders.

"At Bristol-Myers Squibb, we are rooted in our commitment to patients with cardiovascular disease. We are proud to partner with Janssen on our shared vision for advancing cutting-edge science to develop potential new treatments such as BMS-986177 for serious cardiovascular disease," said Tom Lynch, M.D., executive vice president and chief scientific officer, Bristol-Myers Squibb. "By combining the strength of our companies’ extensive expertise in the development and commercialization of cardiovascular treatments, we can maximize the potential of FXIa inhibition."

Bristol-Myers Squibb has a strong heritage of pioneering research and advancing the development of novel compounds to address areas of high unmet need for patients with serious cardiovascular conditions. The collaboration will leverage both companies’ resources and expertise to establish a broad development program across multiple indications.

Janssen will pay Bristol-Myers Squibb an upfront sum along with potential development and regulatory milestone payments. The companies will share development costs and commercial profits and losses. Additional terms of the agreement were not disclosed.

About Factor XIa

Factor XIa (FXIa) plays a key role in the activation and amplification of the coagulation cascade via the intrinsic pathway.i It was first noticed as a potential approach to thrombosis because people with little or no FXIa (Hemophilia C) show virtually no untoward bleeding in the absence of a major injury or surgery. Further, a small study of Hemophilia C patients showed a lower risk of stroke. Conversely, elevated levels of FXI /FXIa are a risk factor for stroke and venous thromboembolism.

Preclinical and early clinical studies suggest that selectively inhibiting the intrinsic branch of the coagulation cascade at an upstream protease such as FXIa could be a key strategy to reducing the risk of vascular events without increasing the risk of bleeding.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Most Popular Now

Scientists uncover SARS-CoV-2-specific T cell immu…

The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore Ge...

Common FDA-approved drug may effectively neutraliz…

A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in ...

Drug linked to 45% lower risk of dying among COVID…

Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be ...

Neutralizing antibodies isolated from COVID-19 pat…

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing ...

GSK and CureVac announce strategic mRNA technology…

GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialis...

Pfizer and BioNTech granted FDA Fast Track designa…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced that two of the companies' four investigational vaccine candidates from their BNT162 mRNA-bas...

Sanofi and Regeneron provide update on Kevzara® (s…

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Phase 3 trial of Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical v...

Novartis launches first-of-its-kind not-for-profit…

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms o...

COVID-19 vaccine AZD1222 showed robust immune resp…

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-Co...

Another mRNA-based vaccine candidate protects anim…

An experimental messenger RNA (mRNA)-based vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits protective immune responses in mice and no...

Pfizer and BioNTech announce an agreement with U.S…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of...

Pfizer and BioNTech announce agreement with the Un…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candid...